Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review

Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review

Treatment of cancer pain is generally based on the three-step World Health Organization (WHO) pain relief ladder, which utilizes a sequential approach with drugs of increasing potency. Goals of pain management include optimization of analgesia, optimization of activities of daily living, minimizatio...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Pain Research Vol. 10; pp. 1963 - 1972
Main Authors: Ahn, Jin Seok, Lin, Johnson, Ogawa, Setsuro, Yuan, Chen, O'Brien, Tony, Le, Brian Hc, Bothwell, Andrea M, Moon, Hanlim, Hadjiat, Yacine, Ganapathi, Abhijith
Format: Journal Article Book Review
Language:English
Published: New Zealand Dove Medical Press Limited 01-01-2017
Taylor & Francis Ltd
Dove Medical Press
Subjects:
Analgesics
Bioavailability
Buprenorphine
Cancer pain
Cancer therapies
Constipation
Dosage and administration
Drug dosages
Drug therapy
Fentanyl
Hematology
Hospitals
Narcotics
Oncology
opioid analgesics
Pain management
Palliative care
Patient compliance
Quality of life
Review
Systematic review
Transdermal medication
transdermal patch
Asia
China
Singapore
pain management
patch analgesics
drug evaluation
cancer pain management
chronic pain/drug therapy
analgesia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of cancer pain is generally based on the three-step World Health Organization (WHO) pain relief ladder, which utilizes a sequential approach with drugs of increasing potency. Goals of pain management include optimization of analgesia, optimization of activities of daily living, minimization of adverse effects, and avoidance of aberrant drug taking. In addition, it is recommended that analgesic regimens are individualized and simplified to help ensure patient compliance and should provide the least invasive, easiest, and safest route of opioid administration to ensure adequate analgesia. Buprenorphine and fentanyl are two opioids available for the relief of moderate-to-severe cancer pain. Available clinical data regarding the transdermal (TD) formulations of these opioids and the extent to which they fulfill the recommendations mentioned earlier are systematically reviewed, with the aim of providing additional information for oncologists and pain specialists regarding their comparative use. Due to lack of studies directly comparing TD buprenorphine with TD fentanyl, data comparing these with other step-3 opioids are also evaluated in a network fashion.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1178-7090
1178-7090
DOI:10.2147/jpr.s140320